Monographie - Polymyxine B

Última actualización :
08/05/2024

Polymyxine B

Estructura química

Nombre comercial

Los nombres comerciales son orientativos y los excipientes de la formulación pueden ser distintos dependiendo del país y del laboratorio fabricante.

Polymyxin B

Estados Unidos de América, Países Bajos

Bibliografía : Polymyxine B

	Tipo	Publicación
384	Periódico	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of esmolol hydrochloride and various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 630-632.
3121	Periódico	He J, Figueroa DA, Lim TP, Chow DS, Tam VH. Stability of polymyxin B sulfate diluted in 0.9% sodium chloride injection and stored at 4 or 25 °C Am J Health-Syst Pharm 2010 ; 67: 1191-1194.
3540	Laboratorio	Heparin sodium - Summary of Product Characteristics. Wockhardt 2010
3838	Laboratorio	Magnesium Sulphate - Summary of Product Characteristics Martindale Pharmaceuticals Ltd 2007
3895	Periódico	Lim Tze-Peng, Kim-Hor Hee D, Lee W, Qi-Min Teo J, Cai Y,Yu-Hng Chia S, Yee-Kiat Leaw J, Jing-Yi Lee S, Soon-U Lee L, Kwa A.L. Physicochemical Stability Study of Polymyxin B in Various Infusion Solutions for Administration to Critically Ill Patients Ann Pharmacotherapy 2016 ; 50: 790-792.
4528	Periódico	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4801	Periódico	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:

Mentions Légales